Loading...
Loading...
India's fluticasone imports from UNITED STATES total $54.3M across 243 shipments from 15 foreign suppliers. AVS RX INC leads with $41.8M in import value; the top 5 suppliers together control 96.6% of this origin. Leading Indian buyers include GLENMARK PHARMACEUTICALS LIMITED. This corridor reflects India's pharmaceutical import demand for fluticasone — a diversified sourcing base with multiple active suppliers from UNITED STATES.

AVS RX INC is the leading Fluticasone supplier from UNITED STATES to India, with import value of $41.8M across 1 shipments. The top 5 suppliers — AVS RX INC, ADIRAMEDICA LLC, TEVA PHARMACEUTICALS USA, ESPEE BIOPHARMA & FINECHEM LLC, PHARMACEUTICAL BUYERS, INC — collectively account for 96.6% of total import value from this origin.
Ranked by import value (USD) · Indian Customs (DGFT) data
| # | Supplier | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | AVS RX INC | $41.8M | 1 | 77.1% |
| 2 | ADIRAMEDICA LLC | $9.4M | 4 | 17.3% |
| 3 | TEVA PHARMACEUTICALS USA | $567.7K | 10 | 1.0% |
| 4 | ESPEE BIOPHARMA & FINECHEM LLC | $325.3K | 23 | 0.6% |
| 5 | PHARMACEUTICAL BUYERS, INC | $266.2K | 7 | 0.5% |
| 6 | GREENE-VAN PHARMACY CORP | $166.8K | 6 | 0.3% |
| 7 | ESPEE BIOPHARMA & FINECHEM LLC. | $131.7K | 13 | 0.2% |
| 8 | AMSTERDAM PHARMA | $128.8K | 1 | 0.2% |
| 9 | SPRING BIO SOLUTION, | $117.8K | 1 | 0.2% |
| 10 | INWOOD PHARMA INC. | $116.5K | 15 | 0.2% |
| 11 | AMSTERDAM PHARMA (APTEKA RX INC.) | $103.3K | 4 | 0.2% |
| 12 | Teva Pharmaceuticals USA | $100.5K | 2 | 0.2% |
| 13 | ESPEE BIOPHARMA FNECHEM LLC | $98.2K | 1 | 0.2% |
| 14 | NEWLIFE MEDICALS (USA). INC. | $90.8K | 6 | 0.2% |
| 15 | PHARMACEUTICAL BUYERS INC | $71.1K | 1 | 0.1% |
Ranked by import value (USD)
| # | Buyer | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | GLENMARK PHARMACEUTICALS LIMITED | $42.4M | 32 | 78.2% |
| 2 | LUPIN LIMITED | $9.8M | 39 | 18.0% |
| 3 | CIPLA LIMITED | $1.3M | 90 | 2.4% |
| 4 | ECRON ACUNOVA LIMITED | $245.4K | 5 | 0.5% |
| 5 | MACLEODS PHARMACEUTICALS LTD | $127.7K | 5 | 0.2% |
| 6 | AUROBINDO PHARMA LTD | $125.5K | 10 | 0.2% |
| 7 | DR.REDDY'S LABORATORIES LTD | $112.5K | 11 | 0.2% |
| 8 | WATSON PHARMA PRIVATE LIMITED | $39.2K | 1 | 0.1% |
| 9 | CIPLA LIMITED. | $36.0K | 4 | 0.1% |
| 10 | SUN PHARMACEUTICAL INDUSTRIES LIMITED | $25.8K | 7 | 0.0% |
| 11 | MACLEODS PHARMACEUTICALS LIMITED | $20.2K | 1 | 0.0% |
| 12 | CADILA HEALTHCARE LIMITED | $16.0K | 16 | 0.0% |
| 13 | ZYDUS LIFESCIENCES LIMITED | $10.6K | 9 | 0.0% |
| 14 | TROIKAA PHARMACEUTICALS LIMITED | $5.9K | 3 | 0.0% |
| 15 | ENCUBE ETHICALS PRIVATE LIMITED | $2.7K | 4 | 0.0% |
Answers based on Indian Customs (DGFT) import records compiled by TransData Nexus
The top Fluticasone suppliers from UNITED STATES to India include AVS RX INC, ADIRAMEDICA LLC, TEVA PHARMACEUTICALS USA. The leading supplier is AVS RX INC with import value of $41.8M USD across 1 shipments. India imported Fluticasone worth $54.3M USD from UNITED STATES in total across 243 shipments.
India imported Fluticasone worth $54.3M USD from UNITED STATES across 243 shipments. Data is from Indian Customs (DGFT) records. Values are in USD.
The main Indian buyers of Fluticasone sourced from UNITED STATES include GLENMARK PHARMACEUTICALS LIMITED, LUPIN LIMITED, CIPLA LIMITED. The largest buyer is GLENMARK PHARMACEUTICALS LIMITED with $42.4M in imports across 32 shipments.
The total value of Fluticasone imports from UNITED STATES to India is $54.3M USD, across 243 shipments and 15 foreign suppliers. Data source: Indian Customs (DGFT).
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
243 Verified Shipments
15 suppliers, 15 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists